JAMA Oncology : Oncolytic Viral Immunochemotherapy in Patients With Ovarian Cancer
Interview with Robert W. Holloway, MD, and Sarfraz Ahmad, PhD, authors of Clinical Activity of Olvimulogene Nanivacirepvec–Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial. Hosted by Jack West, MD. Related Content: Clinical Activity of Olvimulogene Nanivacirepvec–Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - May 25, 2023 Category: General Medicine Authors: The JAMA Network Source Type: podcasts

What is the accuracy of different combinations of ultrasound imaging and blood tests to diagnose ovarian cancer in women before and after the menopause?
Hundreds of Cochrane reviews have been published over the last 25 years relevant to the diagnosis and treatment of a wide range of cancers, including ovarian cancer. In a new review from July 2022, Clare Davenport, from the University of Birmingham in the UK, and colleagues examined the evidence on the use of multiple tests to detect it and she tells us what they found in this podcast. (Source: Podcasts from The Cochrane Library)
Source: Podcasts from The Cochrane Library - November 9, 2022 Category: General Medicine Authors: Cochrane Source Type: podcasts

Stress Ulcer Prophylaxis with PPIs vs H2RBs, Polygenic Risk Scores for Predicting CVD, HMG-CoA Reductase Inhibition and Ovarian Cancer, and more
Editor's Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the February 18, 2020 issue (Source: JAMA: This Week's Audio Commentary)
Source: JAMA: This Week's Audio Commentary - February 18, 2020 Category: General Medicine Authors: JAMA Network Source Type: podcasts

Talk Evidence - Sepsis, talc and blindsided by blinding
Welcome to the festive talk evidence, giving you a little EBM to take you into the new year. As always Duncan Jarvies is joined by Helen Macdonald (resting GP and editor at The BMJ) and Carl Heneghan (active GP, director of Oxford University ’s CEBM and editor of BMJ Evidence)* This month: (1.20) Carl tells us about new research on treating sepsis with steroids that might inform practice. (4.58)Proscribing of prophylactic PPIs or H2-blockers for intensive care patients. (11.00) Carl wonders if we can actually rule out an increased risk of ovarian cancer with the use of talc. (17.46) Helen drops and EBM bombshell - i...
Source: The BMJ Podcast - January 22, 2020 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts

Talk Evidence - Sepsis, talc and blindsided by blinding
Welcome to the festive talk evidence, giving you a little EBM to take you into the new year. As always Duncan Jarvies is joined by Helen Macdonald (resting GP and editor at The BMJ) and Carl Heneghan (active GP, director of Oxford University’s CEBM and editor of BMJ Evidence)* This month: (1.20) Carl tells us about new research on treating sepsis with steroids that might inform practice. (4.58)Proscribing of prophylactic PPIs or H2-blockers for intensive care patients. (11.00) Carl wonders if we can actually rule out an increased risk of ovarian cancer with the use of talc. (17.46) Helen drops and EBM bombshell - is...
Source: The BMJ Podcast - January 22, 2020 Category: General Medicine Authors: BMJ Group Source Type: podcasts

Effect of Folic Acid and Zinc on Semen Quality and Infertility Outcomes, Genital Talc Use and Ovarian Cancer, Fostering Physician Presence and Connection With Patients, and more
Editor's Summary by Preeti Malani, MD, MSJ, Associate Editor of JAMA, the Journal of the American Medical Association, for the January 07, 2020 issue (Source: JAMA: This Week's Audio Commentary)
Source: JAMA: This Week's Audio Commentary - January 7, 2020 Category: General Medicine Authors: JAMA Network Source Type: podcasts

Jack Stewart discusses SOR-C18 potential in different cancers
Jack Stewart, CSO of Soricimed Biopharma elaborates on how SOR-C18 potentially showing promise in ovarian, metastatic prostate and pancreatic cancer. Author: Cancer-News Added: 08/23/2019 (Source: Oncology Tube)
Source: Oncology Tube - August 23, 2019 Category: Cancer & Oncology Source Type: podcasts

Kimberly Halla, MSN, FNP-C - Realizing the Promise of PARP Inhibitors in Solid Tumor Therapy: Guiding Oncology Nurses on the Advances and Challenges
Go online to PeerView.com/KWE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView MasterClass, an expert panel of oncology nurse professionals presents the highlights of emerging science and clinical data on PARP inhibition in multiple solid tumors, assesses the role of companion diagnostic tests that identify patients with DDR mutations, as well as engage the audience in a stimulating discussion on the value of genetic testing and significance of enrollment in ongoing PARP inhibitor clinical trials. Going beyond the standard didactic lectures, our experts...
Source: PeerView CME/CE Audio Podcast - Oncology - June 5, 2019 Category: Cancer & Oncology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts

PARP Inhibitor Therapy for Ovarian Cancer: Practical Prescribing and Medication Management
Earn CME credit: <a target='_blank' href='https://www.naccme.com/program/2018-i7956-1'>https://www.naccme.com/prog...</a><br /><br />PARP inhibitors are the most commonly used targeted therapy for patients with recurrent ovarian cancer, and the indications for the use ... Author: imedex Added: 04/03/2019 (Source: Oncology Tube)
Source: Oncology Tube - April 3, 2019 Category: Cancer & Oncology Source Type: podcasts

Evaluating Clinical Pathways for Ovarian Cancer Treatment and Maintenance Therapy
Earn CME credit for this activity: <a target='_blank' href='https://www.naccme.com/program/2018-802-03'>https://www.naccme.com/prog...</a><br /><br />This on-demand activity examines the implications of BRCA mutational status, BRCAness, synthetic lethality, and within-... Author: imedex Added: 03/06/2019 (Source: Oncology Tube)
Source: Oncology Tube - March 6, 2019 Category: Cancer & Oncology Source Type: podcasts

JAMA Oncology : Analgesic Use and Risk of Ovarian Cancer in the Nurses ’ Health Studies
Interview with Mollie E. Barnard, ScD, and Shelley Tworoger, PhD, authors of Association of Analgesic Use With Risk of Ovarian Cancer in the Nurses’ Health Studies, and Andrew T. Chan, MD, MPH, author of Association Between Aspirin Use and Risk of Hepatocellular Carcinoma (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - October 4, 2018 Category: General Medicine Source Type: podcasts

Quality of life can impact PFS in ovarian cancer
The diagnosis of ovarian cancer often occurs in the late stages due to a lack of adequate screening facilities. However, it is coming to light that the patients quality of life may be just as importa... Author: VJOncology Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts

Stop Screening for Early Ovarian Cancer, USPSTF Says
There is no evidence that screening actually improves outcomes in ovarian cancer, according to a USPSTF analysis of the best available data. (Source: Medscape Oncology)
Source: Medscape Oncology - April 13, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts